One encouraging phase I/II trial combining the mTORC1 inhibitor everolimus with the hyperCVAD chemotherapy regimen found that 5/10 heavily pre-treated T-ALL patients demonstrated clinically-meaningful responses [47], but additional trials dedicated to testing the efficacy of targeting PI3K/AKT/mTOR specifically in T-ALL are needed. This evidence concerns the gene AKT1 and acute lymphoblastic leukemia.